In April 2022, as part of our commitment to make healthcare more affordable and accessible, we invested in Us2.ai, the developer of an AI echocardiography software that enables earlier detection and treatment of heart disease.

Us2.ai uses machine learning to automate the fight against heart disease. Its FDA- and HSA- approved AI software automatically processes the analysis and reporting of echocardiography (heart ultrasound) to deliver accurate cardiac measurements in under two minutes.

In comparison, it takes up to an hour to get the result of a conventional echocardiography. In Singapore and Malaysia, we have begun exploring the use of Us2.ai in cardiac screening. With this we will be able to deliver better and faster care to our patients.